Farxiga

This page shows the latest Farxiga news and features for those working in and with pharma, biotech and healthcare.

J&J’s Invokana first SGLT2 to show kidney disease benefits

The trial puts Invokana one step ahead of rivals, such as AstraZeneca, the renal outcomes study for its SGLT2 drug Farxiga due in November 2020.

Latest news

Success for AZ, setback for Sanofi in type 1 diabetes

The EMA acknowledges the risk but has nevertheless approved Farxiga, while it seems that the FDA has taken a more cautious stance on the side effect and decided not to approve
Cancer drugs and China sustain AZ’s return to growth

Among AZ’s older products, diabetes therapy Farxiga (dapagliflozin) grew 30% to consolidate its blockbuster status with sales of $1.39bn, with an even faster take-up in emerging markets, while
FDA adcomm split on Sanofi’s type 1 diabetes drug

Current SGLT2-selective drugs – such as Johnson &Johnson’s Invokana, Eli Lilly/Boehringer Ingelheim's Jardiance and Farxiga from AstraZeneca – are approved only for type 2 diabetes.
AZ says target of $45bn sales by 2023 still achievable

AZ’s CEO also highlighted diabetes therapy Farxiga (dapagliflozin), which grew by a third to $994m in the nine-month period despite a tough competitive environment. ... The study showed Farxiga cut hospitalisations for heart failure and cardiovascular
New cancer drugs can’t quite plug the revenue hole at AZ

Other bright spots for AZ included the continued growth if antiplatelet drug Brilinta (ticagrelor), up 18% to $609m, diabetes drug Farxiga (dapagliflozin) which leaped 36% to $639m, and new asthma drug

More from news
Approximately 4 fully matching, plus 26 partially matching documents found.

Latest Intelligence

China: AstraZeneca’s new engine for growth and innovation

One of its latest launches in the country is Farxiga, its contender in the SGLT2 inhibitor diabetes market.
Transforming times at AstraZeneca

and was the pharma company with the most approvals from the US FDA with four last year, including the diabetes drug Farxiga (dapagliflozin) and Lynparza (olaparib) for ovarian cancer.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Senior / Principal Medical Writer - MedComms - Home Based / Vari...: Excellent Remuneration Packages

Project Manager - Digital Healthcare - London: Excellent Remuneration Package

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Account Manager, MedicalCommunications/ Healthcare PR: benefits

PR Associate Director – Consumer Health & Beauty: Salary TBC

Senior Medical Writer: Salary TBC

Project Manager - Medical Communications – South Wales: Excellent Remuneration Package

Account Manager / Senior Account Manager - Healthcare Advertisin...: Excellent Remuneration

Editorial / Copy Lead – Healthcare Advertising – Central London...: Salary TBC

Account Director – London based Medical Communications Agency: Excellent Remuneration Package

Account Director, Medical Education: Salary TBC

Director – Healthcare PR: Salary TBC

Home-based Principal Medical Writer – Medical Comms: Salary TBC

Senior Account Director/ Associate Director- Pharma and Life Sci...: Competitive salary and benefits

Hybrid Role - Principal Medical Writer / Account Handler - Publi...: Salary TBC

Freelance Medical Writer - Healthcare Advertising - London: Employment Type:. Type of Job:. Region:. Salary:. 250 to 330 per day

Experienced / Senior Account Director - Publications - London: Up to £80, 000 plus great benefits

Editorial/ Medical Director – Med Ed & Comms – Home-based...: Salary TBC

Senior Medical Writer: Competitive salary and benefits

Editor – Medical Education Agency – Bucks: Salary TBC

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Senior Account Manager- Pharma and Life Scienes: Competitive salary and benefits

Subscribe to our email news alerts

PMHub

Add my company

Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality: How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA: Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad: Six behaviours separate the good brand teams from the bad...